| Chronic Disease Management Strategies | Lifetime | 66 | DE 2 | 99.23 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 123 | DE 8 | 99.33 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 160 | DE 3 | 99.33 |
| Cardiac Health and Mental Health | Lifetime | 291 | DE 5 | 97.91 |
| Blood Pressure and Hypertension Studies | Lifetime | 617 | DE 18 | 98.26 |
| Health and Medical Studies | Lifetime | 182 | DE 172 | 97.09 |
| Health Promotion and Cardiovascular Prevention | Lifetime | 117 | DE 8 | 97.46 |
| Acute Myocardial Infarction Research | Lifetime | 680 | DE 44 | 98.02 |
| Genetic Associations and Epidemiology | Lifetime | 463 | DE 25 | 97.58 |
| Metabolism, Diabetes, and Cancer | Lifetime | 747 | DE 40 | 97.41 |
| Cardiovascular Disease and Adiposity | Lifetime | 697 | DE 40 | 96.69 |
| Heart Failure Treatment and Management | Lifetime | 736 | DE 38 | 97.49 |
| Long-Term Effects of COVID-19 | Lifetime | 858 | DE 37 | 94.67 |
| Diabetes Management and Education | Lifetime | 412 | DE 13 | 96.16 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 675 | DE 47 | 96.04 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | Lifetime | 648 | DE 30 | 93.35 |
| Gout, Hyperuricemia, Uric Acid | Lifetime | 908 | DE 28 | 87.48 |
| Long-Term Effects of COVID-19 | 2021-2025 | 673 | DE 36 | 94.61 |
| COVID-19 and Mental Health | 2021-2025 | 668 | DE 44 | 94.75 |
| Genetic Associations and Epidemiology | 2021-2025 | 361 | DE 11 | 93.08 |
| Acute Myocardial Infarction Research | 2021-2025 | 466 | DE 23 | 94.54 |
| Acute Ischemic Stroke Management | 2021-2025 | 949 | DE 80 | 93.52 |
| Adipokines, Inflammation, and Metabolic Diseases | 2021-2025 | 297 | DE 25 | 87.93 |
| Fibromyalgia and Chronic Fatigue Syndrome Research | 2021-2025 | 301 | DE 23 | 89.83 |
| Cardiovascular Disease and Adiposity | 2021-2025 | 700 | DE 18 | 84.50 |
| IL-33, ST2, and ILC Pathways | 2021-2025 | 718 | DE 45 | 77.80 |
| Nutrition, Genetics, and Disease | 2021-2025 | 673 | DE 29 | 72.82 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | 2021-2025 | 483 | DE 22 | 72.98 |
| Blood properties and coagulation | 2021-2025 | 963 | DE 54 | 52.95 |
| Health Promotion and Cardiovascular Prevention | 2021-2025 | 910 | DE 67 | 44.73 |
| Apelin-related biomedical research | 2021-2025 | 720 | DE 28 | 34.02 |
